UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 23, 2004
Shire Pharmaceuticals Group plc
(Exact name of registrant as specified in its charter)England and Wales
(State or other jurisdiction of incorporation)
0-29630
(Commission File Number) | 98-0359573
(IRS Employer Identification No.) |
Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code 44 1256 894 000
(Former name or former address, if changed since last report)
Item 8.01. Other Events
Shire Pharmaceuticals Group plc has issued the press releases attached as Exhibit 99.01 and Exhibit 99.02 which are incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(c) Exhibits. The following exhibits are filed herewith:
| 99.01 | Press Release dated August 23, 2004; and |
| 99.02 | Press Release dated August 23, 2004. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | SHIRE PHARMACEUTICALS GROUP PLC |
| | | |
| | By: | /s/ A C Russell |
| | |
|
| | | Name: Angus Russell |
| | | Title: Chief Financial Officer |
Dated: August 23, 2004
EXHIBIT INDEX
| 99.01 | Press Release dated August 23, 2004 |
| 99.02 | Press Release dated August 23, 2004 |
